DPP4 resistant mimetics of these endogenous peptides such as exendin-4 and liraglutide, offer extended plasma half-life as compared to endogenous hormone and they are used therapeutically for the treatment of type 2 diabetes mellitus (T2DM) [3]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.